Heart disease still gets Vyndaquel – now Idar Berget still dares to believe in old age – news Møre og Romsdal – Local news, TV and radio

Idar Berget has the serious heart disease amyloidosis. The heart chamber becomes smaller and smaller and works worse and worse – until one day it is completely over. To this day, the only medicine that can help has been so expensive that the government has refused Norwegian patients to get it. Today the day turned. – It means that I get the medicine and can stop the development of the disease, so that I have a chance to continue to have a good life, says Idar Berget. Now probably several hundred patients will receive the medicine. The experts disagree about how many, the estimates vary from 400 to 3,000 Norwegian patients. The decision-making forum for New Methods has dealt with the case three times before and said no. Today is the day yes. It is these tablets that the Decision Forum for New Methods has agreed to. Photo: JONAS OTNEIM / news – Big demand General Secretary Frode Jahren in the National Association for Heart and Lung Disease says they have had an unusually large demand for the case. They have fought for heart disease to be allowed to use the medicine Vyndaquel. – The effect is very, very good. People get many more, good years of life. For these patients, this is absolutely crucial, he says. Former employees in the spring start LHL and several large patient organizations a signature campaign. The goal was for the Norwegian government to conclude more quickly and spend more money on new methods and forms of treatment. Secretary General Frode Jahren of the National Association for Heart and Lung Disease. Photo: LHL Meiner’s prize has too much to say Storting politician Sylvi Listhaug is one of those who have repeatedly asked questions in the Storting about why patients with heart disease do not receive the medicine. She also believes that they have no real chance of complaining and having their case processed, as long as the Decision Forum has said no to the only treatment that helps. A monthly dose has previously cost up to 200,000 kroner, and this is the main reason why the health service has so far said no. – Overall, we believe that price is emphasized too highly when medicines are to be approved, and the health benefits for patients are underestimated. Those who lose out on it are Norwegian patients, who have to wait far too long for medication they need, says Listhaug. Parliamentary representative Sylvi Listhaug (Frp) thinks the health service looks too much at the price. Photo: William Jobling / news Førebur trial Idar Berget in Vanylven is an active man, summer and winter, and has put in countless hours for the ski group at Åheim. In his professional life, he has held key positions at Olivinfabrikken in his home village. In recent weeks, the pensioner has spent a lot of time in recent weeks preparing a lawsuit against the State. A good health insurance meant that he was able to get the expensive medicine himself, after the health service had said no several times. But then it had already been a year. – I have lost time, and it has led to problems with heart failure. I have not concluded whether I will go to court and will discuss the case with my lawyer, he says.



ttn-69